ArticleProtein science : a publication of the Protein Society2024
AMPActiPred: A three-stage framework for predicting antibacterial peptides and activity levels with deep forest.
Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping knowledge landscapes and emerging trends in artificial intelligence for antimicrobial resistance: bibliometric and visualization analysis.Frontiers in medicine · 2025Pooled it
- De Novo Multi-Mechanism Antimicrobial Peptide Design via Multimodal Deep Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Artificial Intelligence-Driven Discovery and Optimization of Antimicrobial Peptides Targeting ESKAPE Pathogens and Multidrug-Resistant Fungi.Microorganisms · 2026Review
- Prediction of minimum inhibitory concentration of antibacterial peptides using geometric graph networks and dynamic loss functions.Briefings in bioinformatics · 2026Article
- Artificial Intelligence as a Catalyst for Antimicrobial Discovery: From Predictive Models to De Novo Design.Microorganisms · 2026Review
- ANIA: an inception-attention network for predicting minimum inhibitory concentration of antimicrobial peptides.Briefings in bioinformatics · 2026Article
- Hybrid and conjugated antimicrobial peptides: new tactics to counter bacterial resistance.Frontiers in microbiology · 2026Review
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
- Transfer learning on protein language models improves antimicrobial peptide classification.Scientific reports · 2025Article
- Pepxml: ESM2-based extreme multilabel classification of pathogen-targeted antimicrobial peptides.Briefings in bioinformatics · 2025Article
- AAGP integrates physicochemical and compositional features for machine learning-based prediction of anti-aging peptides.Scientific reports · 2025Article
- AEPMA: peptide-microbe association prediction based on autoevolutionary heterogeneous graph learning.Briefings in bioinformatics · 2025Article
- Advancing the accuracy of tyrosinase inhibitory peptides prediction via a multiview feature fusion strategy.Scientific reports · 2025Article
- Prediction of inhibitory peptides against E.coli with desired MIC value.Scientific reports · 2025Article
- Explainable Artificial Intelligence in the Field of Drug Research.Drug design, development and therapy · 2025Review
- AI Methods for Antimicrobial Peptides: Progress and Challenges.Microbial biotechnology · 2025Review
- Article
- TG-CDDPM: text-guided antimicrobial peptides generation based on conditional denoising diffusion probabilistic model.Briefings in bioinformatics · 2024Article
- DeepBP: Ensemble deep learning strategy for bioactive peptide prediction.BMC bioinformatics · 2024Article
- HemoFuse: multi-feature fusion based on multi-head cross-attention for identification of hemolytic peptides.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The emergence and spread of antibiotic-resistant bacteria pose a significant public health threat, necessitating the exploration of alternative antibacterial strategies. Antibacterial peptide (ABP) is a kind of antimicrobial peptide (AMP) that has the potential ability to fight against bacteria infection, offering a promising avenue for developing novel therapeutic interventions. This study introduces AMPActiPred, a three-stage computational framework designed to identify ABPs, characterize their activity against diverse bacterial species, and predict their activity levels. AMPActiPred employed multiple effective peptide descriptors to effectively capture the compositional features and physicochemical properties of peptides. AMPActiPred utilized deep forest architecture, a cascading architecture similar to deep neural networks, capable of effectively processing and exploring original features to enhance predictive performance. In the first stage, AMPActiPred focuses on ABP identification, achieving an Accuracy of 87.6% and an MCC of 0.742 on an elaborate dataset, demonstrating state-of-the-art performance. In the second stage, AMPActiPred achieved an average GMean at 82.8% in identifying ABPs targeting 10 bacterial species, indicating AMPActiPred can achieve balanced predictions regarding the functional activity of ABP across this set of species. In the third stage, AMPActiPred demonstrates robust predictive capabilities for ABP activity levels with an average PCC of 0.722. Furthermore, AMPActiPred exhibits excellent interpretability, elucidating crucial features associated with antibacterial activity. AMPActiPred is the first computational framework capable of predicting targets and activity levels of ABPs. Finally, to facilitate the utilization of AMPActiPred, we have established a user-friendly web interface deployed at https://awi.cuhk.edu.cn/∼AMPActiPred/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.